Third-line and beyond treatment in mCRC and sequencing

Conflicto de intereses: los autores declaran no tener conflicto de inters.Inteligencia artificial: los autores declaran no haber usado inteligencia artificial (IA) ni ninguna herramienta que use IA para la redaccin del artculo. RESUMENtherapeutic standard.Emerging targeted strategies against KRAS G12C, BRAF V600E and HER2, as well as the limited effectiveness of immunotherapy in MSS tumors, are critically addressed.Finally, a therapeutic algorithm is proposed to optimize treatment sequencing and to support clinical decision-making in a scenario where incremental benefit remains modest.